CAMP4 Therapeutics Corporation (CAMP)
CAMP trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:Revenues), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1736730/000173673026000016/0001736730-26-000016-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | CAMP on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | 2024 |
| SEC CIK | 0001736730 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | DE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $3.5M |
| Net income | -$80.4M |
| Operating income | -$52.6M |
| Net margin | -2298.5% |
| Operating margin | -1502.4% |
| Revenue growth | +436.5% |
| Cash | $109.5M |
| Total assets | $117.8M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 69.2× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 10-Q 2026-11-05 |
| Cash and burn | $124.5M cash; operating cash flow -$6.4M a quarter. | Report 2026-09-30 |
| Shares outstanding | 62,754,200 (2026-11-04); 46,881,134 a year earlier. | Cover page 2026-11-04 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 1 S-3/F-3 shelf filings; 2 424B5 takedowns, 2 at the market | Latest 2025-12-18 |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | Ernst & Young LLP, Boston, Massachusetts, United States | PCAOB Form AP 2026-03-24 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $77K, sold $2.5M on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | $1.9M | -$29.0M | -$8.2M | $124.5M | No debt tags | $5.3M | 10-Q 2026-11-05 |
| Q2 2026 2026-06-30 | $1.8M | -$33.5M | -$12.7M | $86.4M | No debt tags | $4.2M | 10-Q 2026-08-13 |
| Q1 2026 2026-03-31 | $1.3M | -$18.3M | -$11.0M | $99.2M | No debt tags | $3.9M | 10-Q 2026-05-07 |
| Q4 2025 2025-12-31 | $348K | -$40.3M | $6.3M | $109.5M | No debt tags | $3.5M | 10-K 2026-03-05 |
| Q3 2025 2025-09-30 | $795K | -$15.1M | -$11.2M | $75.3M | No debt tags | Needs four quarters | 10-Q 2026-11-05 |
| Q2 2025 2025-06-30 | $1.5M | -$12.6M | -$10.3M | $39.1M | No debt tags | Needs four quarters | 10-Q 2026-08-13 |
| Q1 2025 2025-03-31 | $858K | -$12.4M | -$14.3M | $49.3M | No debt tags | Needs four quarters | 10-Q 2026-05-07 |
| Q4 2024 2024-12-31 | Not filed | -$13.3M | -$11.3M | $64.0M | No debt tags | $652K | 10-K 2026-03-05 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B3 | 2026-08-12 |
| Latest annual report | 10-K | 2026-03-05 |
| Latest quarterly / interim | 10-Q | 2026-11-05 |
| Latest current report | 8-K | 2026-11-05 |
| Latest proxy | DEFA14A | 2026-04-23 |
Source: SEC EDGAR submissions feed, 195 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -6.4% |
| 1 month | +10.8% |
| 3 months | -15.6% |
| Year to date | -38.0% |
| 1 year | -11.0% |
| From 52-week high | -46.7% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| LFCR | Lifecore Biomedical Inc. | $6.42 | -0.08% | $243.2M |
| RCKT | Rocket Pharmaceuticals Inc. | $2.16 | -6.09% | $241.2M |
| BIOA | BioAge Labs Inc. | $5.22 | -5.95% | $239.9M |
| FTH | Faeth Therapeutics Inc. | $9.28 | -7.48% | $239.8M |
| ARCT | Arcturus Therapeutics Holdings Inc. | $8.31 | -0.60% | $239.5M |
| QTTB | Q32 Bio Inc. | $8.29 | -4.82% | $248.1M |
| AMRN | Amarin Corporation plc | $11.31 | -0.62% | $233.4M |
| VNDA | Vanda Pharmaceuticals Inc. | $3.81 | -4.51% | $230.4M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier